Company:  ONCOGENEX PHARMACEUTICALS ... (OGXI)
Form Type:  8-K
Filing Date:  2/2/2012 
CIK:  0000949858 
Address:  1522 217TH PLACE S.E. 
City, State, Zip:  BOTHELL, Washington 98021 
Telephone:  (425) 487-9500 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$10.52  
Change: 
0.09 (0.86%)  
Trade Time: 
04:00 PM EST  
Market Cap: 
$154.84M
Description of Business
We are a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. We have three product candidates in our pipeline: custirsen, apatorsen and OGX-225, each of which has a distinct mechanism of action and represents a unique opportunity for cancer drug development. Of the product candidates in our pipeline, custirsen and apatorsen are clinical-stage assets. Product Candidates Overview and Recent Developments Our product candidates focus on mechanisms of treatment resistance in cancer patients and are designed to block the production of specific proteins that we believe promote treatment resistance and survival of tumor cells and are over-produced in response to a variety of cancer treatments.
Register for EDGAR Pro and access this filing in:     
  FORM 8-K
    SECTION 7 REGULATION FD
      Item 7.01 Regulation FD Disclosure.
    SECTION 9 FINANCIAL STATEMENTS AND EXHIBITS
      Item 9.01 Financial Statements and Exhibits.
    SIGNATURES
    EXHIBIT INDEX
  EXHIBIT 99.1
  EXHIBIT 99.2
BROKERAGE PARTNERS